HDAC9 and myelodysplastic syndrome: While the former is FDA-approved for myelodysplastic syndromes (MDS), histone deacetylase (HDAC) inhibitors have gained FDA-approved for T-cell cutaneous lymphoma and multiple myeloma (Kaminskas et al., 2005; Azad et al., 2013).